OnLume announced recently that it is beginning a clinical trial for its fluorescence-guided surgery (FGS) imaging device, which will be combined with a novel nerve-targeting agent.

The Phase I-II study, which uses Alume Bioscience’s ALM-488, will take place at the University of California at San Diego, Stanford Medical Center and Harvard-Massachusetts Eye & Ear.

“We are excited to work with Dr. Quyen Nguyen’s (Alume) team on this groundbreaking clinical trial that may help to significantly reduce or prevent nerve injuries during surgery,” OnLume Co-Founder Adam Uselmann said in a statement.

According to a release, OnLume has unique FGS imaging technology to illuminate critical anatomy in real-time during surgery to optimize surgical precision, which can lead to improved patient outcomes, reduced morbidity and reduced costs.